Liraglutide
Also known as: Victoza · Saxenda
The predecessor long-acting GLP-1 receptor agonist to semaglutide, with the completed ELAD Phase II trial in Alzheimer's disease — the reference cognitive-endpoint trial for the GLP-1 class before EVOKE.
Liraglutide is a licensed long-acting GLP-1 receptor agonist (Victoza/Saxenda) with the completed ELAD Phase II Alzheimer's trial — positive imaging biomarkers, negative primary cognitive endpoints.
Evidence tier: A — ≥1 RCT + meta-analysis or approved clinical use
- Category
- Neuroprotection
- Half-life
- Approximately 13 hours plasma
Section 1
Overview
Liraglutide is a long-acting synthetic analogue of glucagon-like peptide-1 (GLP-1), engineered with a fatty-acid modification that binds albumin to confer extended plasma half-life and enable once-daily subcutaneous dosing. It is an authorised pharmaceutical: the EMA lists Victoza and Saxenda as centrally authorised in the EU; in the UK the emc lists Saxenda and liraglutide 6 mg/ml pre-filled pens (a search of the emc for Victoza returned no entry on 17 October 2026), and the MHRA Drug Safety Update lists liraglutide among authorised GLP-1 receptor agonists; Drugs@FDA lists Victoza and Saxenda as approved.
For cognitive-relevance research on this reference, liraglutide is important primarily as the compound that established the pattern that semaglutide went on to test at Phase III. The ELAD trial — Evaluating Liraglutide in Alzheimer's Disease — was the pioneering Phase II randomised placebo-controlled trial evaluating a GLP-1 agonist in mild-to-moderate Alzheimer's disease. Results published in 2020 reported positive effects on imaging biomarkers (reduced brain glucose hypometabolism) but negative primary cognitive endpoints, providing mixed evidence that motivated the subsequent semaglutide EVOKE programme.
As an older-generation GLP-1 analogue with a completed cognitive-endpoint trial (albeit with mixed results), liraglutide provides an important reference point for interpreting the emerging cognitive-relevance evidence base for the GLP-1 class as a whole.
Section 2
Discovery & History
- Developed by Novo Nordisk as the first long-acting GLP-1 receptor agonist for daily subcutaneous administration, with the fatty-acid modification enabling once-daily dosing.
- Received FDA approval in 2010 for type-2 diabetes (as Victoza) and subsequently for obesity (as Saxenda, 2014).
- Substantial post-marketing safety database from millions of licensed-indication patient-years.
- The ELAD Phase II Alzheimer's trial was conducted in the mid-2010s and results published in 2020 with mixed cognitive-endpoint findings.
- The semaglutide EVOKE Phase III programme followed ELAD as the main cognitive-endpoint trial programme for the GLP-1 class and did not show slowed clinical progression in early Alzheimer's disease (Lancet, 2026); the ELAD data remains an important reference point.
Section 3
Mechanism of Action
- 1Direct GLP-1 receptor agonism — the mechanism shared with semaglutide and other GLP-1 analogues; sustained receptor activation drives multiple downstream effects across metabolic, cardiovascular, and central-nervous-system targets.
- 2Extended plasma half-life via albumin-binding fatty-acid modification (a palmitoyl group attached via a glutamic-acid spacer), enabling once-daily subcutaneous dosing versus the minutes-long half-life of native GLP-1.
- 3Central GLP-1 receptor activation — GLP-1 receptors are expressed on CNS neuronal populations in the hippocampus, hypothalamus, and other cognitively-relevant regions, providing the anatomical substrate for the AD cognitive-therapeutic research angle.
- 4Improvement of central insulin signalling and brain glucose utilisation — the mechanism-of-action angle for AD applications, motivated by the characterisation of Alzheimer's disease as involving central insulin resistance ('type 3 diabetes').
- 5Reduction of neuroinflammation — measurable effects on microglial activation phenotype, decreased pro-inflammatory cytokine expression (TNF-α, IL-1β, IL-6), and reduced neuroinflammatory cascade activation in AD-model preparations.
- 6Metabolic effects on weight, glucose regulation, and cardiovascular parameters that indirectly reduce the vascular-and-metabolic contribution to cognitive decline via reduced hypertension, improved lipid profile, and reduced cerebrovascular disease burden.
- 7Reported effects on BDNF expression in preclinical AD-model animals, linking the compound to the broader BDNF-mediated cognitive-plasticity pathway that dominates the cognitive-peptide field.
- 8Anti-amyloid effects reported in transgenic AD-model animals — reduced amyloid-beta accumulation, preserved neuronal viability, and improved cognitive-endpoint performance in the preclinical evidence base.
Section 4
Researched Benefits
Findings reported in the published preclinical and clinical literature. Effects in research contexts do not constitute claims of therapeutic benefit in humans.
- 1Licensed clinical use in type-2 diabetes (Victoza) and obesity (Saxenda) with substantial post-marketing safety database across millions of patient-years.
- 2Completed ELAD Phase II Alzheimer's trial providing the first Phase II cognitive-endpoint evidence for the GLP-1 class — mixed results but positive imaging biomarkers.
- 3Positive brain-imaging biomarker findings in ELAD (reduced brain glucose hypometabolism, a validated marker of AD pathology) despite the negative primary cognitive endpoint.
- 4Substantial post-marketing safety database from millions of patient-years of licensed-indication use, providing chronic-use safety confidence unmatched by most cognitive-relevance peptides.
- 5Cardiovascular and metabolic-syndrome benefits demonstrated in the LEADER cardiovascular outcome trial, extending the licensed-indication evidence base.
- 6Authorised UK prescription-only medicine (emc), a different supply position from peptides with no marketing authorisation.
- 7Preclinical anti-amyloid and BDNF-induction evidence extending the mechanism-of-action framework beyond the metabolic-syndrome-mediated indirect cognitive effect.
Section 5
Theoretical Dosing & Protocols
| Route | Dosage | Frequency | Duration | Source |
|---|---|---|---|---|
| Subcutaneous injection (Saxenda) | Licensed dose for weight management (SmPC): start 0.6 mg once daily; increase in steps of 0.6 mg at intervals of at least one week to 3.0 mg once daily. Daily doses above 3.0 mg are not recommended | Once daily | Dose steps of at least one week, as set out in the SmPC | emc SmPC: Saxenda (section 4.2) |
| Subcutaneous injection (liraglutide 6 mg/ml pre-filled pen) | Licensed dose for type 2 diabetes mellitus (SmPC): start 0.6 mg once daily; after at least one week 1.2 mg; some patients may benefit from 1.8 mg after at least a further week. Daily doses above 1.8 mg are not recommended | Once daily | Dose steps of at least one week, as set out in the SmPC | emc SmPC: Liraglutide Biocon 6 mg/ml (section 4.2) |
Note: Not licensed for cognitive indications; cognitive-endpoint use is limited to completed research trials.
Note: Not licensed for cognitive indications.
Section 6
Administration Routes
- Subcutaneous injection — the licensed clinical route for both Victoza (diabetes) and Saxenda (obesity) indications; typically abdominal, thigh, or upper-arm administration.
- The ELAD cognitive-endpoint trial used the same subcutaneous route at the standard licensed-indication doses.
- Oral administration is not viable for liraglutide (contrasting with semaglutide's Rybelsus oral formulation) — the fatty-acid modification enables plasma half-life extension but does not confer oral bioavailability.
- Intranasal and transdermal delivery have not been developed clinically for liraglutide.
Section 7
Safety Profile
Commonly reported
- · Gastrointestinal effects — nausea, vomiting, diarrhoea, constipation — the most common tolerability signal and the principal reason for discontinuation across the licensed clinical experience.
- · Injection-site reactions with subcutaneous administration; typically mild and self-limiting.
- · Reduced appetite and satiety effects — the pharmacology behind the weight-loss indication and expected in all patients on the compound.
- · Headache during dose titration, typically resolving as the tolerance-adaptation curve completes.
- · Mild transient effects on heart rate reported at low frequency in the licensed clinical experience.
Rare / theoretical
- · Acute pancreatitis — reported at low but non-zero frequency in licensed clinical experience; requires discontinuation and clinical evaluation if suspected.
- · Gallbladder disease and cholelithiasis with rapid weight loss — a mechanism-related concern that applies to the whole GLP-1 class in weight-loss contexts.
- · Thyroid C-cell tumours — theoretical concern from rodent carcinogenicity studies; contraindicated in patients with medullary thyroid carcinoma and MEN 2 syndrome (a class-wide contraindication).
- · Diabetic retinopathy complications reported at low frequency, primarily in the diabetes population with pre-existing retinopathy.
- · Rare hypersensitivity reactions.
Contraindications
- · Personal or family history of medullary thyroid carcinoma or MEN 2 syndrome.
- · Type 1 diabetes and diabetic ketoacidosis.
- · Pregnancy and breastfeeding.
- · Severe gastrointestinal disease.
Section 8
UK & EU Regulatory Context
United Kingdom
Authorised in the UK as prescription-only medicines: the electronic medicines compendium (emc) lists Saxenda (weight management) and liraglutide 6 mg/ml pre-filled pens from several marketing authorisation holders (checked 17 October 2026), and the MHRA Drug Safety Update lists liraglutide among the GLP-1 receptor agonists authorised in the UK for type 2 diabetes mellitus and, for some products, weight management. Cognitive indications are not among the indications in the Saxenda SmPC.
European Union
Authorised centrally in the EU: the EMA lists Victoza (2009) and Saxenda (2015) as authorised.
Section 9
Clinical Studies Summary
Liraglutide in Alzheimer's disease — ELAD Phase II trial
The pioneering Phase II randomised placebo-controlled trial of liraglutide in mild-to-moderate Alzheimer's disease, evaluating cognitive-endpoint effects over 52 weeks of daily subcutaneous liraglutide versus placebo. Results reported positive imaging-biomarker findings (reduced brain glucose hypometabolism on FDG-PET) but negative primary cognitive endpoints, providing mixed evidence that motivated the subsequent semaglutide EVOKE Phase III programme. The trial is the reference cognitive-endpoint evidence for the GLP-1 class before EVOKE.
Liraglutide cardiovascular and metabolic outcome trials (LEADER)
LEADER Phase III cardiovascular outcome trial in 9,340 type-2 diabetes patients establishing liraglutide's cardiovascular safety and demonstrating a significant reduction in major adverse cardiovascular events over 3.8-year median follow-up. Provided the licensed-indication cardiovascular-safety evidence base and the mortality-benefit finding that supported broader clinical adoption.
GLP-1 receptor agonism and central insulin signalling
Mechanistic characterisation of GLP-1 receptor expression and signalling in the CNS applied specifically to liraglutide, demonstrating central GLP-1 receptor activation with downstream effects on insulin signalling, glucose utilisation, and BDNF expression in the hippocampus. Provides the mechanism-of-action scaffold for the AD cognitive-therapeutic research angle that ELAD tested.
Liraglutide anti-amyloid effects in transgenic AD models
Preclinical characterisation in APP/PS1 double-transgenic Alzheimer's disease mouse models reporting reduced amyloid-beta accumulation, preserved cognitive performance on hippocampus-dependent learning tasks, and increased hippocampal BDNF expression in liraglutide-treated cohorts. Provides the preclinical mechanistic basis for the AD cognitive-endpoint research angle that ELAD subsequently tested clinically.
Liraglutide in weight-loss indication (SCALE trials)
The SCALE trial programme establishing liraglutide's weight-reduction efficacy in obese and overweight populations, providing the licensed-indication evidence base for the Saxenda formulation and demonstrating a mean weight reduction of approximately 8% over 56 weeks in the pivotal trials.
Section 10
Frequently Asked Questions
Section 10a